GSDME enhances Cisplatin sensitivity to regress non-small cell lung carcinoma by mediating pyroptosis to trigger antitumor immunocyte infiltration

Peng, Zhouyangfan; Wang, Pengfei; Song, Wei; Yao, Qingmei; Li, Yinjia; Liu, Linglong; Li, Yapei; Zhou, Sufang

doi:10.1038/s41392-020-00274-9

Cited by 66 publications

(71 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pyroptosis in cancer generates abundant neoantigens, which are processed by antigen-presenting cells to promote the formation of antigen-specific cytotoxic T lymphocyte (CTL), thereby evoking anti-tumor immunity. Combination of pyroptosis-inducible therapeutic regimens with ICIs enhances anti-tumor immune responses and promotes tumor regression, achieving longterm control of cancer tumor immunity, which enhances the ability of cisplatin to regress non-small cell lung cancer [120]. Our group found that the natural product triptolide exerts tumor suppression activity through inducing GSDME-mediated pyroptosis in head and neck cancer cells (unpublished data), highlighting its potential to serve as an adjuvant approach for cancer immune therapy.…”

Section: Induction Of Pyroptotic Cell Death By Chemotherapy Drugsmentioning

confidence: 84%

“…Induction of sustainable anti-tumor immunity may improve the efficacy of cancer chemotherapy. Induction of GSDME-mediated pyroptosis evokes anti-tumor immunity, which enhances the ability of cisplatin to regress non-small cell lung cancer [ 120 ]. Our group found that the natural product triptolide exerts tumor suppression activity through inducing GSDME-mediated pyroptosis in head and neck cancer cells (unpublished data), highlighting its potential to serve as an adjuvant approach for cancer immune therapy.…”

Section: Main Textmentioning

confidence: 99%

See 1 more Smart Citation

Pyroptosis: a new paradigm of cell death for fighting against cancer

Tan

Chen

et al. 2021

J Exp Clin Cancer Res

300

217

View full text Add to dashboard Cite

Background Unraveling the mystery of cell death is one of the most fundamental progresses of life sciences during the past decades. Regulated cell death (RCD) or programmed cell death (PCD) is not only essential in embryonic development, but also plays an important role in the occurrence and progression of diseases, especially cancers. Escaping of cell death is one of hallmarks of cancer. Main body Pyroptosis is an inflammatory cell death usually caused by microbial infection, accompanied by activation of inflammasomes and maturation of pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18). Gasdermin family proteins are the executors of pyroptosis. Cytotoxic N-terminal of gasdermins generated from caspases or granzymes proteases mediated cleavage of gasdermin proteins oligomerizes and forms pore across cell membrane, leading to release of IL-1β, IL-18. Pyroptosis exerts tumor suppression function and evokes anti-tumor immune responses. Therapeutic regimens, including chemotherapy, radiotherapy, targeted therapy and immune therapy, induce pyroptosis in cancer, which potentiate local and systemic anti-tumor immunity. On the other hand, pyroptosis of normal cells attributes to side effects of anti-cancer therapies. Conclusion In this review, we focus on the regulatory mechanisms of pyroptosis and the tumor suppressive function of pyroptosis. We discuss the attribution of pyroptosis in reprogramming tumor microenvironments and restoration of anti-tumor immunity and its potential application in cancer immune therapy.

show abstract

Section: Induction Of Pyroptotic Cell Death By Chemotherapy Drugsmentioning

confidence: 84%

Section: Main Textmentioning

confidence: 99%

Pyroptosis: a new paradigm of cell death for fighting against cancer

Tan

Chen

et al. 2021

J Exp Clin Cancer Res

300

217

View full text Add to dashboard Cite

show abstract

“…The chemotherapeutic drug cisplatin regulates the release of immune factors in the induction of GSDME-mediated pyroptosis, and the level of MIP-1a, MIP-1b, MIP-2 and IP-10 in tumor tissues and blood are increase. Peng et al think that it is precisely the release of immune factors that recruits T cells in tumor tissues and trigger anti-tumor effect (80).…”

Section: Pyroptosis With Tumors Lung Cancer and Pyroptosismentioning

confidence: 99%

“…Peng et al. think that it is precisely the release of immune factors that recruits T cells in tumor tissues and trigger anti-tumor effect ( 80 ).…”

Section: Pyroptosis With Tumorsmentioning

confidence: 99%

Pyroptosis, a New Breakthrough in Cancer Treatment

Wei

et al. 2021

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

The way of cell death can be roughly divided into two categories: cell necrosis and PCD(programmed cell death). Pyroptosis is a kind of PCD, its occurrence depends on the gasdermin protein family and it will produce inflammatory response. With constant research in recent years, more and more evidences show that pyroptosis is closely related to the occurrence and development of tumors. The treatment of tumors is a big problem worldwide. We focus on whether we can discover new potential tumor markers and new therapeutic targets from the mechanism. If we can understand the mechanism of pyroptosis and clear the relationship between pyroptosis and the development of tumors, this may provide a new reference for clinical cancer treatment.

show abstract

“…According to the published literatures, various types of cell death, including cell apoptosis [26][27][28], necroptosis [29,30], ferroptosis [31,32], and pyroptosis [33][34][35], involve in regulating cisplatin-resistance in cancers. Especially, cell apoptosis [26][27][28] and pyroptosis [33][34][35] are two types of programmed cell death that participate in the regulation of cisplatin-resistance in NSCLC, and researchers notice that there exist interplays between apoptotic and pyroptotic cell death [36,37].…”

Section: Introductionmentioning

confidence: 99%